Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy.
It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin.
It does not bind to active myostatin, activin A, active BMP9/10 or TGFβ1 that all operate on the activin type 2 receptors.
[1][2][3]